

Jessica M Fogel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8686100/publications.pdf>

Version: 2024-02-01

36
papers

757
citations

567281

15
h-index

552781

26
g-index

36
all docs

36
docs citations

36
times ranked

1207
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. <i>Journal of Infectious Diseases</i> , 2022, 225, 1741-1749.	4.0	35
2	HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART). <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	3
3	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. <i>Journal of Infectious Diseases</i> , 2021, 224, 1581-1592.	4.0	72
4	Under-Reporting of Known HIV-Positive Status Among People Living with HIV: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2021, 25, 3858-3870.	2.7	11
5	PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003670.	8.4	87
6	HIV drug resistance in a cohort of HIV-infected MSM in the United States. <i>Aids</i> , 2020, 34, 91-101.	2.2	16
7	Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3510-3516.	3.0	13
8	Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART). <i>Journal of the International AIDS Society</i> , 2020, 23, e25452.	3.0	8
9	Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic. <i>PLoS ONE</i> , 2020, 15, e0240890.	2.5	4
10	HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074. <i>PLoS ONE</i> , 2019, 14, e0223829.	2.5	11
11	Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075. <i>AIDS and Behavior</i> , 2019, 23, 289-294.	2.7	18
12	Use of Antiretroviral Drug Testing to Assess the Accuracy of Self-reported Data from HIV-Infected People Who Inject Drugs. <i>AIDS and Behavior</i> , 2019, 23, 2101-2108.	2.7	14
13	Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. <i>Journal of Clinical Virology</i> , 2018, 99-100, 67-70.	3.1	7
14	HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 484-491.	2.1	10
15	Antiretroviral Drug Use and HIV Drug Resistance Among Young Women in Rural South Africa: HPTN 068. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 315-322.	2.1	4
16	Natural control of HIV infection in young women in South Africa: HPTN 068. <i>HIV Clinical Trials</i> , 2018, 19, 202-208.	2.0	4
17	Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa. <i>Aids</i> , 2018, 32, 1301-1306.	2.2	15
18	Virologic outcomes in early antiretroviral treatment: HPTN 052. <i>HIV Clinical Trials</i> , 2017, 18, 100-109.	2.0	20

#	ARTICLE	IF	CITATIONS
19	Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 112-116.	2.1	54
20	Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 158-165.	2.1	8
21	Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. <i>PLoS ONE</i> , 2017, 12, e0177281.	2.5	3
22	Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 304-309.	2.1	14
23	Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 446-452.	2.1	21
24	Determination of HIV Status in African Adults With Discordant HIV Rapid Tests. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 430-438.	2.1	7
25	Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies. <i>Vaccine Journal</i> , 2015, 22, 806-816.	3.1	19
26	A Comparison of Referred Sexual Partners to Their Community Recruited Counterparts in The BROTHERS Project (HPTN 061). <i>AIDS and Behavior</i> , 2015, 19, 2214-2223.	2.7	7
27	Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa. <i>Journal of Clinical Virology</i> , 2015, 62, 75-79.	3.1	6
28	Nondisclosure of HIV Status in a Clinical Trial Setting: Antiretroviral Drug Screening Can Help Distinguish Between Newly Diagnosed and Previously Diagnosed HIV Infection. <i>Clinical Infectious Diseases</i> , 2014, 58, 117-120.	5.8	52
29	Failure to Identify HIV-Infected Individuals in a Clinical Trial Using a Single HIV Rapid Test for Screening. <i>HIV Clinical Trials</i> , 2014, 15, 62-68.	2.0	17
30	Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	4.0	68
31	Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-infected Breastfeeding Infants. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e164-e169.	2.0	31
32	Stavudine Concentrations in Women Receiving Postpartum Antiretroviral Treatment and Their Breastfeeding Infants. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 462-465.	2.1	5
33	Use of a High Resolution Melting Assay to Analyze HIV Diversity in HIV-infected Ugandan Children. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e222-e228.	2.0	12
34	Initiation of Antiretroviral Treatment in Women After Delivery Can Induce Multiclass Drug Resistance in Breastfeeding HIV-Infected Infants. <i>Clinical Infectious Diseases</i> , 2011, 52, 1069-1076.	5.8	47
35	Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. <i>Aids</i> , 2011, 25, 911-917.	2.2	18
36	Association of HIV Diversity and Survival in HIV-Infected Ugandan Infants. <i>PLoS ONE</i> , 2011, 6, e18642.	2.5	16